Clinical trials: Neoadjuvant Treatment
Bilateral Breast Carcinoma, HER2/Neu Negative
Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy
This phase II trial studies how well ixabepilone compared with standard of care works in treating patients with HER2/Neu negative breast cancer that remains after undergoing systemic therapy.
- Conditions
- Bilateral Breast Carcinoma, HER2/Neu Negative, Invasive Breast Carcinoma
- Trial name
- NCT00877500
- Testing
- Best Practice, Ixabepilone
- Where
- 3 sites in United States
- Volunteers
- 116 people
- Sponsor
- M.D. Anderson Cancer Center
Ulcerative Colitis (UC)
Efficacy of Upadacitinib Re-induction Therapy in Patients With Ulcerative Colitis Who Lost Response to 30 mg Maintenance Dose
ReCOUP is a multicenter clinical study designed to evaluate the efficacy of upadacitinib (Rinvoq®) in patients with ulcerative colitis whose disease has become active again despite maintenance treatment with upadacitinib 30 mg.
- Trial name
- ReCOUP (NCT07700446)
- Testing
- Upadacitinib
- Volunteers
- 100 people
- Sponsor
- Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
Pancreatic Cancer
Phase 2 Study of Oral MKC-1 in Patients With Unresectable or Metastatic Pancreatic Cancer
To determine the antitumor activity of MKC-1 in patients with unresectable or metastatic pancreatic cancer who have failed at least one prior chemotherapy regimen in either the neoadjuvant, adjuvant, or first-line metastatic…
- Trial name
- NCT00568646
- Testing
- MKC-1
- Where
- 2 sites in United States
- Volunteers
- 33 people
- Sponsor
- CASI pharmaceuticals, Inc.
Hepatocellular Carcinoma Resectable
A Clinical Study of Tislelizumab Combined With TACE and Lenvatinib in the Neoadjuvant Treatment of Resectable HCC
In order to improve the R0 resection rate, reduce distant metastasis, and lower postoperative recurrence, there is a growing exploration of surgical treatments for hepatocellular carcinoma (HCC), including preoperative…
- Trial name
- NCT06003673
- Testing
- neoadjuvant therapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- First Affiliated Hospital of Fujian Medical University
Leukemia
Arsenic Trioxide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia
RATIONALE: Drugs used in chemotherapy, such as arsenic trioxide, cytarabine, and idarubicin, work in different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00093483
- Testing
- filgrastim, arsenic trioxide, cytarabine
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Roswell Park Cancer Institute
HER2-positive Breast Cancer
Asian Multicenter Prospective Study in HER2 Positive Early Breast Cancer for Detecting MRD by ctDNA;HARMONY Study
This study will assess minimal residual disease (MRD) in HER2-positive early breast cancer patients in Asian countries. The purpose is to evaluate the relation between the detection rate of MRD and recurrence.
- Trial name
- NCT05433753
- Where
- Japan
- Volunteers
- 60 people
- Sponsor
- National Cancer Center, Japan
Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
A Single-Arm Study of QL1706 Combined With DOS as Neoadjuvant Therapy for Locally Advanced Gastric/GEJ Adenocarcinoma
This is an open-label, prospective, interventional study designed to enroll 34 patients with locally advanced gastric or gastroesophageal junction adenocarcinoma, aiming to evaluate and observe the efficacy and safety of QL1706…
- Trial name
- NCT07828873
- Testing
- Iparomlimab and Tuvonralimab Injection (QL1706), Docetaxel, Oxaliplatin
- Where
- China
- Volunteers
- 34 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Rectal Cancer
Neoadjuvant Radiochemotherapy Combined With QL1706 for Low Rectal Cancer
This study investigates the efficacy of neoadjuvant radiotherapy combined with QL1706 in MSS-type low-grade rectal cancer. This study is a prospective multicohort study, with cohort 1 intended to include patients with low grade…
- Trial name
- NCT06931873
- Testing
- SCRT+Capoex+QL706, LCRT+Capoex+QL706
- Volunteers
- 60 people
- Sponsor
- Changhai Hospital
Multiple Myeloma
Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy
To assess Minimal Residual Disease (MRD)-negative Complete Response (sCR) rate after consolidation treatment with Descartes-11 in patients with high-risk myeloma who have residual disease following induction therapy.
- Trial name
- NCT04436029
- Testing
- Descartes 11
- Where
- 4 sites in United States
- Volunteers
- 5 people
- Sponsor
- Cartesian Therapeutics
Pancreas Adenocarcinoma
24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC
The purpose of this research is to study the effects and safety of alternating neoadjuvant chemotherapy on borderline resectable pancreatic cancer.
- Trial name
- NCT07043270
- Testing
- Nab-paclitaxel + Gemcitabine, modified FOLFIRINOX (mFOLFIRINOX)
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Malignant Neoplasms of Male Genital Organs, Prostate Cancer
Neoadjuvant Listeria or Daratumumab in Prostate Cancer
The goal of this clinical research study is to learn about biomarker changes in patients who have primary prostate cancer after receiving Darzalex (daratumumab) and then have a prostatectomy (the surgical removal of the prostate)…
- Trial name
- NCT03035357
- Testing
- Daratumumab
- Sponsor
- M.D. Anderson Cancer Center
HNSCC, Lysogenic HSV Virus
A Clinical Study on Neoadjuvant Treatment of Resectable Head and Neck Squamous Carcinoma With Immune-targeted Therapy and Lysogenic HSV Virus
Evaluation of the safety and tolerability of immune-targeted therapy combined with neoadjuvant therapy with lysogenic HSV virus for patients with surgically resectable squamous carcinoma of the head and neck.
- Conditions
- HNSCC, Lysogenic HSV Virus, Neoadjuvant Therapy, Immunotherapy
- Trial name
- NCT06741982
- Testing
- Lysogenic HSV virus., Tislelizumab, Afatinib
- Where
- China
- Sponsor
- West China Hospital
Non-small Cell Lung Cancer Stage IB, Non-small Cell Lung Cancer Stage II
Neoadjuvant Therapy of Pembrolizumab + Ramucirumab for PD-L1 Positive Stage IB-IIIA Lung Cancer (EAST ENERGY)
The efficacy and safety of the neoadjuvant therapy of pembrolizumab+ ramucirumab
- Conditions
- Non-small Cell Lung Cancer Stage IB, Non-small Cell Lung Cancer Stage II, Non-small Cell Lung Cancer Stage ⅢA
- Trial name
- NCT04040361
- Testing
- Pembrolizumab, Ramucirumab, Surgery
- Where
- 2 sites in Japan
- Volunteers
- 24 people
- Sponsor
- National Cancer Center Hospital East
NSCLC
TALENT Study: Phase II Trial of Adjuvant L-TIL Plus Tislelizumab in Resectable NSCLC Without pCR After Neoadjuvant Chemoimmunotherapy
This study evaluates the preliminary efficacy and safety of adjuvant therapy with liquid tumor-infiltrating lymphocytes (L-TIL) in combination with tislelizumab in patients with resectable stage II-IIIB non-small cell lung cancer…
- Trial name
- NCT07330037
- Testing
- L-TIL cells injection, Tislelizumab
- Where
- China
- Volunteers
- 41 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Ovarian Cancer
Efficacy of Primary Debulking Surgery Versus Neoadjuvant Chemotherapy in Stage IV Ovarian Cancer
Epithelial ovarian cancer is mostly diagnosed at late stage (III/IV), and the standard treatment for ovarian cancer includes primary debulking surgery and platinum-based adjuvant chemotherapy.
- Trial name
- NCT05371301
- Testing
- Paclitaxel, Carboplatin, debulking surgery
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Fudan University
Small-Cell Carcinoma of the Esophageal
Efficacy and Safety of Serplulimab Combined With Etoposide and Cisplatin as Neoadjuvant Therapy in Limited-Stage Small-Cell Carcinoma of the Esophageal
This study is a prospective, single-center, single-arm phase II clinical trial designed to evaluate the efficacy and safety of serplulimab in combination with etoposide and platinum-based chemotherapy as neoadjuvant treatment for…
- Trial name
- NCT07155122
- Testing
- Drug: Serplulimab, Drug: Etoposide, Drug: Chemotherapy
- Volunteers
- 15 people
- Sponsor
- Fujian Cancer Hospital
Metastatic Colorectal Cancer
Pattern of Cell Death Following Neoadjuvant Therapy for Metastatic Colon Cancer
Systemic chemotherapy for metastatic colon cancer is often used in the neoadjuvant setting for patients undergoing liver resection.
- Trial name
- NCT00414492
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Breast Cancer, HER2 Positive
Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2
This study compares two schedules of upfront chemotherapy in HER positive breast cancer.
- Trial name
- TRAIN-2 (NCT01996267)
- Testing
- PTC+Pertuzumab, FEC-T+Pertuzumab
- Where
- 33 sites in Netherlands
- Volunteers
- 437 people
- Sponsor
- The Netherlands Cancer Institute
Breast Cancer, Chemotherapy Effect
Comparison of MRI With PET / CT in the Evaluation of Response to Neoadjuvant Therapy Based on the Molecular Subtypes of Breast Cancer
The current study aims to determine the diagnostic accuracy of Magnetic Resonance Imaging (MRI) and Positron Emission Tomography- Computed Tomography (PET-CT) in predicting a pathological response of molecular subtypes of breast…
- Trial name
- NCT04882371
- Testing
- Chemotherapy, Magnetic Resonance Imaging (MRI), Positron emission tomography - Copmputer Tomography (PET-CT)
- Where
- Turkey (Türkiye)
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Cem Ilgin Erol
Early-Stage Oral Squamous Cell Carcinoma
Neoadjuvant Low-Dose Radiotherapy Combined With Adebrelimab and Single-Agent Albumin-Bound Paclitaxel Chemotherapy for Early-Stage Oral Squamous Cell Carcinoma: A Prospective, Single-Arm Clinical Trial
This is a prospective, single-arm, Phase II clinical trial. The included population consisted of untreated patients with histologically confirmed stage I-II oral squamous cell carcinoma.
- Trial name
- NCT07007364
- Testing
- Adebrelimab Combined With Albumin Paclitaxel
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Jun Jia
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.